We have reported that induction of IGFBP-3 expression by adenoviral infection or by treatment with rBP3 or SCH66336 (a farnesyl transferase inhibitor) suppresses the activities of growth, angiogenesis, and metastasis in NSCLC and HNSCC cells [17, 18]. Here, RBP3 is linked to non-small cell lung carcinoma.